^
CANCER:

Cervical Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
HER-2 mutation
Cervical Cancer
neratinib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
PD-L1 negative
Cervical Cancer
pembrolizumab + tirvalimogene teraplasmid
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
No biomarker
Cervical Cancer
Aybintio (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
bevacizumab-awwb
Sensitive
:
A1
No biomarker
Cervical Cancer
bevacizumab-bvzr
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Cervical Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Cervical Cancer
bevacizumab-maly
Sensitive
:
A1
No biomarker
Cervical Cancer
tisotumab vedotin-tftv
Sensitive
:
A1
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive
:
A1
No biomarker
Cervical Cancer
Krabeva (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
cadonilimab
Sensitive
:
A1
No biomarker
Cervical Cancer
CT-P16 (bevacizumab biosimilar)
Sensitive
:
A1
No biomarker
Cervical Cancer
paclitaxel + topotecan
Sensitive
:
A2
No biomarker
Cervical Cancer
5-fluorouracil
Sensitive
:
A2
No biomarker
Cervical Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
carboplatin
Sensitive
:
A2
No biomarker
Cervical Cancer
vinorelbine tartrate
Sensitive
:
A2
No biomarker
Cervical Cancer
pemetrexed
Sensitive
:
A2
No biomarker
Cervical Cancer
mitomycin
Sensitive
:
A2
No biomarker
Cervical Cancer
irinotecan
Sensitive
:
A2
No biomarker
Cervical Cancer
ifosfamide
Sensitive
:
A2
No biomarker
Cervical Cancer
gemcitabine
Sensitive
:
A2
No biomarker
Cervical Cancer
docetaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Cervical Cancer
topotecan
Sensitive
:
A2
NTRK3 fusion
Cervical Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Cervical Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Cervical Cancer
entrectinib
Sensitive
:
A2
NTRK3 fusion
Cervical Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Cervical Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Cervical Cancer
larotrectinib
Sensitive
:
A2
No biomarker
Cervical Cancer
cisplatin
Sensitive
:
A2
TMB-H
Cervical Cancer
pembrolizumab
Sensitive
:
A2